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Abstract
Objectives—The study objective was to examine the prevalence of maternal multivitamin use 
and associations with preterm birth (<37 weeks gestation) in the United States. We additionally 
examined whether associations differed by race/ethnicity.
Methods—Using the Pregnancy Risk Assessment Monitoring System, we analyzed 2009–2010 
data among women aged ≥18 years with a singleton live birth who completed questions on 
multivitamin use 1 month prior to pregnancy (24 states; n = 57,348) or in the last 3 months of 
pregnancy (3 states, n = 5,095).
Results—In the month prior to pregnancy, multivitamin use ≥4 times/week continued to remain 
low (36.8 %). In the last 3 months of pregnancy, 79.6 % of women reported using multivitamins 
≥4 times/week. Adjusting for confounders, multivitamin use 1–3 times/week or ≥4 times/week 
prior to pregnancy was not associated with preterm birth overall. Though there was no evidence of 
dose response, any multivitamin use in the last 3 months of pregnancy was associated with a 
significant reduction in preterm birth among non-Hispanic black women.
Conclusions—Multivitamin use during pregnancy may help reduce preterm birth, particularly 
among populations with the highest burden, though further investigations are warranted.
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Introduction
In 2014, preterm birth (birth at less than 37 weeks gestation affected an estimated one out of 
ten infants in the United States (16). Most preterm births (approximately 65–70 %) are 
spontaneous, often occurring without a known cause (3, 15). Nearly one-third of infant 
deaths are attributable to preterm birth (6). Surviving preterm infants, particularly the 
smallest and youngest, have an increased risk of neurodevelopmental disabilities, including 
cerebral palsy, hearing impairment, and retinopathy of prematurity (11, 20, 23). 
Furthermore, the societal economic burden associated with preterm birth in the United States 
in 2005 exceeded $26.2 billion (20).
In the United States, there is a persistent racial disparity in preterm birth rates. In 2014, the 
preterm birth rate was 13.2 % among non-Hispanic Black (NHB) women compared to 8.9 % 
among non-Hispanic white (NHW) women. (16). Reasons for racial disparities in preterm 
birth are likely multifactorial and are not completely understood. Possible explanations have 
included genetic, psychosocial, and environmental factors (26).
With increasing recognition of the importance of implantation and formation of the placenta 
for pregnancy outcomes, risk factors for preterm birth have expanded to include the period 
before, during, and soon after conception (5, 22). Current evidence indicates that maternal 
nutritional status before and during pregnancy may influence pregnancy outcomes (5, 7, 8, 
22, 33). Daily consumption of 400 micrograms of folic acid starting at least 1 month before 
conception through early pregnancy is estimated to prevent 50–70 % of neural tube defects 
(9). Iron-deficiency in early pregnancy has been associated with increased risk of preterm 
birth (25). Research also suggests vitamin D deficiency may be associated with adverse 
reproductive outcomes, including preeclampsia, gestational diabetes mellitus, preterm birth, 
or small-for-gestational age (34).
As with preterm birth, racial disparities are also present when comparing the nutritional 
status of NHB and NHW women of reproductive age. In a previous analysis of Pregnancy 
Risk Assessment Monitoring System (PRAMS) 2004 data for 26 states, multivitamin use ≥4 
times per week 1 month prior to pregnancy was lower among NHB women than among 
NHW women (13). Additionally, many national population-based studies have reported 
lower intakes of folic acid as well as lower serum levels of iron and vitamin D among NHB 
than among NHW women of reproductive age (14, 18, 30).
Research examining the association between multivitamin use and preterm birth is limited 
by race/ethnicity, locality, and sample size (7, 8, 12, 33). A previous randomized controlled 
trial in Hungary assessed the effect of periconceptional (a term referring to the time period 
before and soon after conception) multivitamin supplementation on pregnancy and found no 
significant differences in the incidence of preterm birth between the supplementation and 
control groups (12). However, it is possible that results may have been obscured by the fact 
that the control group was also exposed to some micronutrients. Three observational studies 
examining multivitamin use and preterm birth indicated that higher pre- or periconceptional 
multivitamin use was associated with a reduced risk of preterm birth (7, 8, 33), though these 
studies primarily comprised white women. Studies including a broader range of racial/ethnic 
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groups offer insight into whether multivitamin use may explain some of the disparities in 
preterm birth rates.
The purpose of this study was to assess the prevalence of multivitamin use 1 month prior to 
pregnancy or during the last 3 months of pregnancy, and to examine associations with 
preterm birth using multistate, population-based data. Additionally, we examined whether 
associations differed by race/ethnicity.
Methods
We used data from the 2009–2010 PRAMS for this analysis. PRAMS is a population-based 
surveillance system that was established in 1987 by the Centers for Disease Control and 
Prevention (CDC) to monitor reductions in infant mortality and low birth weight in the 
United States. PRAMS provides information on maternal experiences and behaviors before, 
during, and after pregnancy (10). Each year, states participating in PRAMS sample 
information from between 1,300 and 3,400 women who have had a recent live birth, using 
data from each state’s birth files. PRAMS’ method of data collection includes a mailed 
survey and, in the case of nonresponse after repeated mailing attempts, a telephone survey. 
Questionnaire mailing packets and telephone surveys include all required elements of 
informed consent. PRAMS data are linked to birth certificate data and weighted to adjust for 
the sampling design, noncoverage, and nonresponse. Further details about the PRAMS 
methodology have been published elsewhere (27). The PRAMS project was approved by the 
CDC Institutional Review Board.
We included in the analysis states with response rates of ≥65 % that included the PRAMS 
questions related to multivitamin use for the years 2009–2010. Maternal multivitamin use 1 
month prior to pregnancy was evaluated by the response to the question, “During the month 
before you got pregnant with your new baby, how many times a week did you take a 
multivitamin, a prenatal vitamin, or a folic acid vitamin?” The 24 states that included this 
question were Alaska, Arkansas, Colorado, Delaware, Georgia, Hawaii, Maine, Maryland, 
Massachusetts, Minnesota, Missouri, Nebraska, New Jersey, Ohio, Oklahoma, Oregon, 
Pennsylvania, Rhode Island, Texas, Utah, Vermont, Washington, West Virginia, and 
Wyoming (n = 68,426). Maternal multivitamin use during pregnancy was based on the 
response to the question, “During the last 3 months of your most recent pregnancy, how 
many times a week did you take a multivitamin, a prenatal vitamin, or a folic acid vitamin?” 
The 3 states that included this question were Arkansas, Georgia, and Ohio (n = 7,486).
The analysis was limited to women ≥18 years with a singleton live birth (multivitamin use 1 
month prior to pregnancy, 24 states, n = 63,561; multivitamin use in the last 3 months of 
pregnancy, 3 states, n = 6,762). To investigate a possible dose–response relationship between 
multivitamin use and preterm birth, multivitamin use was categorized as 0, 1–3, or ≥4 days/
week. The classification of multivitamin use ≥4 days/week has been used in previous 
PRAMS publications (13, 28). Preterm birth was defined as birth at <37 weeks gestation, 
and early preterm birth as birth at <34 weeks gestation; the information was based on the 
clinical estimate of gestational age at birth as indicated on the birth certificate.
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Covariates included in the analysis have been shown to be associated with maternal 
multivitamin use and preterm birth. Covariates from birth certificate data included maternal 
education (<12 years, 12 years, or >12 years), marital status (yes/no), parity (0, 1, ≥ 2 
previous live births), age, and race/ethnicity. As a result of smaller sample sizes among 
certain racial/ethnic groups, we examined characteristics by race/ethnicity and combined 
groups according to similar patterns. For multivitamin use 1 month prior to pregnancy, race/
ethnicity was categorized as NHW, NHB, Hispanic, American Indian/Alaska Native/
Hawaiian, Asian, or other, and age was categorized as 18–19, 20–24, 25–29, 30–34, 35–39, 
or ≥40 years. For multivitamin use in the last 3 months of pregnancy, race/ethnicity included 
only NHW, NHB, and Hispanic, and age was categorized as 18–19, 20–24, 25–29, or ≥30 
years because of smaller sample sizes in other categories.
Covariates from the PRAMS questionnaire included Medicaid recipient (yes/no), Special 
Supplemental Nutrition Program for Women, Infants, and Children (WIC) recipient (yes/
no), and smoking status during pregnancy. Women who reported smoking in the 3 months 
prior to pregnancy and in the last 3 months of pregnancy on the PRAMS questionnaire were 
categorized as smokers. Women who reported smoking 3 months before pregnancy but not 
in the last 3 months of pregnancy were categorized as quitters. Women who reported no 
smoking at both time points were categorized as nonsmokers. Prepregnancy body mass 
index (<18.5, 18.5–24.9, 25–29.9, and ≥30), was calculated from maternal weight and height 
as reported on the PRAMS questionnaire. Prepregnancy body mass index was coded as 
missing for extreme values (n = 120) based on data distributions for maternal height (<4’0” 
or >6’6”) and prepregnancy weight (<75 pounds or >500 pounds).
Records with missing data for multivitamin use, preterm birth, or covariates were excluded 
(multivitamin use 1 month prior to pregnancy, 24 states, n = 6,107; multivitamin use in the 
last 3 months of pregnancy, 3 states, n = 843). Comparing predictor and outcome variables, 
women included in the study sample were similar to those excluded (data not shown). The 
final study sample for the analysis of multivitamin use prior to pregnancy included 57,348 
women and the final sample for the analysis of multivitamin use the in the last 3 months of 
pregnancy included 5,905 women.
We used SAS-callable SUDAAN version 9.3 (Research Triangle Institute, Research Triangle 
Park, North Carolina) to account for PRAMS’ complex sampling design. Chi-squared tests 
were used to examine bivariate associations between maternal or infant characteristics and 
multivitamin use. We estimated unadjusted and adjusted odds ratios (OR) and 95 % 
confidence intervals (CI) for the association between multivitamin use and preterm birth 
using logistic regression. Because women with certain medical or pregnancy conditions may 
be more likely to have a preterm birth and receive preventive interventions, we also 
conducted a sensitivity analysis excluding women with diabetes mellitus, hypertension and, 
among women with a previous live birth, those with a history of previous preterm birth or 
low birth weight. We evaluated effect modification by race/ethnicity by including an 
interaction term between race/ethnicity and multivitamin use in the model. P values were 
considered significant at <0.05 for main effects and <0.15 for interactions.
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Results
Multivitamin use 1 month prior to pregnancy (24 states)
Maternal characteristics are shown in Table 1. Overall, only 36.8 % of women reported 
using multivitamins ≥4 times per week (data not shown). Multivitamin use ≥4 times per 
week was higher among Asian and NHW women, as well as among women who were older, 
more educated, married, and nonsmoking. Multivitamin use ≥4 times per week was also 
higher among women who reported they were not Medicaid or Women, Infants, and 
Children (WIC) program recipients. Preterm birth (<37 weeks gestation) was highest among 
women who reported using no multivitamins 1 month prior to pregnancy (8.6 %) compared 
to those who reported multivitamin use 1–3 times per week (7.4 %) or ≥4 times per week 
(7.8 %) (Fig. 1). Patterns were similar for early preterm birth (<34 weeks gestation).
The association between multivitamin use 1 month prior to pregnancy and preterm birth was 
not modified by race/ethnicity (p for interaction = 0.17). We found a significant decrease in 
the unadjusted odds of both preterm birth and early preterm birth for women who reported 
multivitamin use ≥4 times per week (Table 2). However, these associations were weakened 
and no longer statistically significant after adjustment for covariates. Associations were 
similar after performing a sensitivity analysis excluding women with diabetes mellitus, 
hypertension, previous preterm birth, or low birthweight (data not shown).
Multivitamin use in the last 3 months of pregnancy (3 states)
Maternal characteristics are shown in Table 3. Overall, 79.6 % of women reported using 
multivitamins ≥4 times per week (data not shown). Multivitamin use ≥4 times per week in 
the last 3 months of pregnancy was higher among women who were older, more educated, 
married, and nonsmoking (Table 3). Multivitamin use ≥4 times per week was also higher 
among women who reported they did not receive Medicaid or Women, Infants, and Children 
benefits. Preterm birth was highest among women who reported using no multivitamins in 
the last 3 months of pregnancy (11.5 %) compared with those who reported multivitamin use 
1–3 times per week (8.5 %) or ≥4 times per week (8.9 %) (Fig. 2). Patterns were similar for 
early preterm birth.
Race/ethnicity modified the association between multivitamin use in the last 3 months of 
pregnancy and preterm birth (P for interaction = 0.09), thus results are presented stratified. 
In the last 3 months of pregnancy, multivitamin use was not associated with preterm birth or 
early preterm birth among NHW or Hispanic women (Table 4). Among NHB women, 
vitamin use in the last 3 months of pregnancy was associated with a significant reduction in 
early preterm birth, but there was no evidence of a dose-response relationship. Categorizing 
multivitamin use in the last 3 months of pregnancy as none versus any (≥1 times per week), 
any multivitamin use was associated with a significant reduction in both preterm [adjusted 
OR 0.51, 95% CI (0.28–0.91)] and early preterm birth [adjusted OR 0.40, 95% CI (0.20–
0.80)] among NHB women. All associations were similar after performing a sensitivity 
analysis excluding women with diabetes mellitus, hypertension, previous preterm birth or 
low birthweight (data not shown).
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Discussion
Overall, 36.8% of women reported using multivitamins ≥4 times per week 1 month prior to 
pregnancy (24 states). Reported multivitamin use 1 month prior to pregnancy was lower 
among American Indian/Alaska Native/Hawaiian, NHB, Hispanic, and Other women than 
among NWH and Asian women. In the last 3 months of pregnancy (3 states), 79.6 % of 
women reported multivitamin use ≥4 times per week, and use was similar across racial/
ethnic groups. The results of this analysis do not support an association between maternal 
multivitamin use in the month prior to pregnancy and preterm birth. Although there was no 
evidence of dose response, any multivitamin use in the last 3 months of pregnancy was 
associated with reduced odds of preterm birth among NHB women.
We observed a similar prevalence of any multivitamin use in the last 3 months of pregnancy 
(90.8 %) for 3 states compared with data from the 1999–2006 National Health and Nutrition 
Examination Survey, which found 89.2 % of women in the third trimester reported using a 
folic acid-containing supplement in the last thirty days (4). In addition, our findings confirm 
that multivitamin use among nonpregnant women of reproductive age remains relatively low. 
The prevalence of any multivitamin use 1 month prior to pregnancy in our study (45.3 %) 
was similar to a 2004 analysis of Behavioral Risk Factor Surveillance System data (47.0 %) 
of nonpregnant women of reproductive age (29). Moreover, our data indicating 36.8 % of 
women report vitamin use ≥4 times per week 1 month prior to pregnancy was consistent 
with a 2004 PRAMS report (35.1 %) (13).
The low level of preconception multivitamin use is somewhat disconcerting given that a 
significant portion of women of reproductive age do not meet recommended intakes for 
important nutrients such as iron, vitamin D, and folate through diet alone (1, 2, 31). 
Nutritional status is important both before pregnancy for the normal development of the 
embryo and in early pregnancy, as nutritional requirements increase to sustain fetal growth 
and maternal metabolism and tissue development (19, 21). Increased amounts of iron are 
required during pregnancy to produce more blood and support the growth of the fetal-
placental unit, while folic acid has been shown to decrease the risk of neural tube defects (9, 
24). Research also suggests that vitamin D may play an anti-inflammatory role during 
pregnancy (35).
Our results are different from previous research on pre- and periconceptional multivitamin 
use comprised primarily of NHW women (7, 8, 33). Our findings may be explained by 
different underlying risks in the various study populations. The etiology of preterm birth is 
multifactorial and the pathways leading to it are complex and poorly understood. Further 
investigation into the relationship between multivitamin use and preterm birth is necessary to 
understand these differences. While we did observe an association between NHB women 
and preterm birth for any vitamin use, additional research among other racial/ethnic groups 
is warranted.
This study has a number of potential limitations attributed to the PRAMS retrospective, 
cross-sectional study design. PRAMS data are self-reported and most participants are 
surveyed 2–3 months following delivery; thus, there may be social desirability and recall 
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bias. In a comparison of self-report data versus an electronic monitoring system among low-
income pregnant women, it was shown that self-reported use of prenatal multivitamin/
mineral supplements was overestimated by 8.4 % (17). Also, PRAMS asks women whether 
they took a multivitamin, a prenatal vitamin, or a folic acid vitamin; thus, we could not 
determine whether just one or a combination of micronutrients was responsible for the 
observed association. Furthermore, multivitamin use during pregnancy is assessed during the 
last 3 months of pregnancy; thus, timing of multivitamin use may differ between those with 
term or preterm births.
The small sample size (3 states) for the study of multivitamin use in the last 3 months of 
pregnancy may have prevented us from finding an association between multivitamin use and 
preterm birth among NHW and Hispanic women. Additionally, PRAMS does not distinguish 
between medically indicated and spontaneous preterm births, which have different risk 
factors and may have limited our ability to detect an association if nutritional status was 
linked only to the development of certain conditions. Lastly, findings are only generalizable 
to the states included in the analyses.
Our study has several strengths. To our knowledge, this is the first study that assesses the 
relationship between multivitamin use and preterm birth during pregnancy by race/ethnicity 
using a multistate data source at the population level. PRAMS uses standardized methods for 
data collection, which allows for a multistate analysis. PRAMS also collects a wide range of 
data, and as a result, this analysis could control for a number of covariates.
In conclusion, as only a third of women with a recent live birth reported using multivitamins 
≥4 times per week in the month prior to pregnancy, the results of our study indicate that 
public health efforts need to be directed toward increasing the prevalence of multivitamin 
use among women of reproductive age, including culturally tailored programs targeted to 
women with lower reported multivitamin use, such as NHB women. Several health 
organizations and initiatives recommend vitamin supplementation among women of 
reproductive age because birth defects can occur very early in pregnancy (3–4 weeks after 
conception) (9, 32). Although nearly 80 % of women reported using multivitamins ≥4 times 
per week in the last 3 months of pregnancy, our results suggest that NHB women who do not 
use multivitamins during pregnancy may have increased odds of preterm birth. Further 
investigations are warranted to understand whether increasing the proportion of women who 
use multivitamins during pregnancy may be an important strategy for reducing preterm birth, 
particularly among those with the highest burden.
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Significance
Current evidence indicates maternal nutritional status before and during pregnancy may 
influence pregnancy outcomes. To our knowledge, this is the first study that assesses the 
relationship between multivitamin use and preterm birth during pregnancy by race/
ethnicity using multistate, population-based data. Although there was no evidence of dose 
response, any multivitamin use in the last three months of pregnancy was associated with 
reduced odds of preterm birth among non-Hispanic black women.
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Figure 1. 
Preterm birth (<37 weeks) by multivitamin use 1 month prior to pregnancy, PRAMS, United 
States, 24 states, 2009–2010. Hashed lines show the proportion of early preterm births that 
were delivered <34 weeks. 24 states include Alaska, Arkansas, Colorado, Delaware, 
Georgia, Hawaii, Maine, Maryland, Massachusetts, Minnesota, Missouri, Nebraska, New 
Jersey, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Texas, Utah, Vermont, 
Washington, West Virginia, and Wyoming. PRAMS Pregnancy Risk Assessment Monitoring 
System. Chi-square p value <37 weeks: 0.04. Chi-square p value <34 weeks: 0.01.
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Figure 2. 
Preterm birth (<37 weeks) by multivitamin use in the last 3 months of pregnancy, PRAMS, 
United States, 3 States, 2009–2010. Hashed lines show the proportion of early preterm births 
that were delivered <34 weeks. 3 states include Arkansas, Georgia, and Ohio. PRAMS 
Pregnancy Risk Assessment Monitoring System. Chi-square p value for <37 weeks: 0.33. 
Chi-square p value for <34 weeks: 0.14.
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